ReviewFrontiers in endocrinology2026
Klinefelter syndrome beyond hypogonadism: multisystem manifestations and a framework for clinical surveillance.
Review in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Klinefelter syndrome (KS) is the most common male sex chromosome aneuploidy, affecting approximately 1 in 450-600 male births. Characterised by a 47,XXY karyotype in the majority of cases, it is widely known for its association with hypergonadotropic hypogonadism, infertility, and impaired testicular function; however, the clinical consequences of the supernumerary X chromosome extend far beyond the reproductive axis. This review provides an updated and integrative overview of the multisystem involvement in KS, with particular emphasis on metabolic derangements, cardiovascular and thromboembolic risk, skeletal health, malignancy patterns, thyroid dysfunction, and neurocognitive outcomes. Emerging concepts, including the bone-testicular axis, the role of insulin-like peptide 3 (INSL3), and osteocalcin-mediated endocrine crosstalk, are critically appraised. Recent data on mortality, accelerated biological ageing, and the systemic impact of testosterone replacement therapy (TRT) are discussed in light of contemporary evidence. Given the substantial burden of comorbidities and the high rate of underdiagnosis, early recognition and implementation of a structured, multidisciplinary surveillance strategy are essential to improve long-term outcomes in individuals with KS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.